Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allogeneic Plasma-based Biomaterial,Calcium Phosphate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Alpha Healthcare Acquisition Corp.
Deal Size : $154.0 million
Deal Type : Merger
Details : Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products...
Brand Name : BHA
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Allogeneic Plasma-based Biomaterial,Calcium Phosphate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Alpha Healthcare Acquisition Corp.
Deal Size : $154.0 million
Deal Type : Merger
Lead Product(s) : Calcium Phosphate,Blood-derived component
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant
Details : The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2020
Lead Product(s) : Calcium Phosphate,Blood-derived component
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Calcium Phosphate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant
Details : Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 07, 2020
Lead Product(s) : Calcium Phosphate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?